Debris Field of the July 19, 2009, Impact in Jupiter and Its Long-term Evolution

A multi-platform suite of imaging and spectroscopic observations of Jupiter\u27s atmosphere tracked the evolution of the debris field of an unknown impactor on 2009 July 19. The initial debris field is similar to those of intermediate Shoemaker-Levy 9 fragments, suggesting a body hundreds of meters in size, if icy, entering from the west and slightly north. The field is detectable in the visible as dark material and in the near-IR by high-altitude particulate reflectivity; it was quickly redistributed by different zonal flows across its latitudinal range. At first, the particulate field was highly correlated with areas of enhanced temperatures and enhanced ammonia and ethane emission, but this was no longer true by mid-August. As of Sept. 2, the debris field was undetectable in the thermal, detectable in the visible with good seeing, and still prominent near 2 microns wavelength. Visibly, the impact scar consists of two dark regions along the same latitude, ostensibly different from the central bright region associated with the near-IR debris pattern. Both morphologies show eastern and western extensions propagating away from the original impact site, which appear to be influenced by flows around vortices previously undetected in Jupiter atmosphere. These observations define the flow field just north of Jupiter\u27s southern polar vortex at higher altitudes than tracked in Jupiter\u27s main cloud deck

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Background: Sparsentan is a novel, non-immunosuppressive, single-molecule, dual endothelin and angiotensin receptor antagonist being examined in an ongoing phase 3 trial in adults with IgA nephropathy. We report the prespecified interim analysis of the primary proteinuria efficacy endpoint, and safety. Methods: PROTECT is an international, randomised, double-blind, active-controlled study, being conducted in 134 clinical practice sites in 18 countries. The study examines sparsentan versus irbesartan in adults (aged ≥18 years) with biopsy-proven IgA nephropathy and proteinuria of 1·0 g/day or higher despite maximised renin-angiotensin system inhibitor treatment for at least 12 weeks. Participants were randomly assigned in a 1:1 ratio to receive sparsentan 400 mg once daily or irbesartan 300 mg once daily, stratified by estimated glomerular filtration rate at screening (30 to 1·75 g/day). The primary efficacy endpoint was change from baseline to week 36 in urine protein-creatinine ratio based on a 24-h urine sample, assessed using mixed model repeated measures. Treatment-emergent adverse events (TEAEs) were safety endpoints. All endpoints were examined in all participants who received at least one dose of randomised treatment. The study is ongoing and is registered with ClinicalTrials.gov, NCT03762850. Findings: Between Dec 20, 2018, and May 26, 2021, 404 participants were randomly assigned to sparsentan (n=202) or irbesartan (n=202) and received treatment. At week 36, the geometric least squares mean percent change from baseline in urine protein-creatinine ratio was statistically significantly greater in the sparsentan group (-49·8%) than the irbesartan group (-15·1%), resulting in a between-group relative reduction of 41% (least squares mean ratio=0·59; 95% CI 0·51-0·69; p<0·0001). TEAEs with sparsentan were similar to irbesartan. There were no cases of severe oedema, heart failure, hepatotoxicity, or oedema-related discontinuations. Bodyweight changes from baseline were not different between the sparsentan and irbesartan groups. Interpretation: Once-daily treatment with sparsentan produced meaningful reduction in proteinuria compared with irbesartan in adults with IgA nephropathy. Safety of sparsentan was similar to irbesartan. Future analyses after completion of the 2-year double-blind period will show whether these beneficial effects translate into a long-term nephroprotective potential of sparsentan. Funding: Travere Therapeutics